Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01440088 · ClinicalTrials.gov registry record · Phase 3
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
A Phase 3 study, sponsored by Threshold Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 640
- Enrollment target
NCT01440088 is a Phase 3 study that has completed, run by Threshold Pharmaceuticals. The registered enrollment target is 640 participants.
The verdict
NCT01440088, a Phase 3 study, has completed, sponsored by Threshold Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 640 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma.
Interventions
- DRUG Doxorubicin
- DRUG TH-302 in Combination with Doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 640 participants |
| Start Date | 2011-09 |
| Est. Completion | 2016-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01440088
The ClinicalTrials.gov registry entry for NCT01440088 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 640 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Threshold Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Doxorubicin is the first listed.
NCT01440088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01440088 about?
NCT01440088 is a clinical study titled "A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma". The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma.
What is the current status of trial NCT01440088?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 640 participants. The study started on 2011-09. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01440088?
The interventions under investigation include: Doxorubicin (DRUG), TH-302 in Combination with Doxorubicin (DRUG).
Who is sponsoring clinical trial NCT01440088?
This trial is sponsored by Threshold Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.